14534 Federal Register / Vol. 87, No. 50 / Tuesday, March 15, 2022 / Notices 

ADDRESSES: You may submit comments 

by mail to: Sherri Diana, National 

Institute for Occupational Safety and 

Health, 1090 Tusculum Avenue, MS C– 

34, Cincinnati, Ohio 45226. 

Meeting Information: Audio 

Conference Call via FTS Conferencing. 

The USA toll-free dial-in number is 1– 

866–659–0537; the pass code is 

9933701. 

Written comments received in 

advance of the meeting will be included 

in the official record of the meeting. The 

public is also welcomed to listen to the 

meeting by joining the audio conference 

(information below). The audio 

conference line has 150 ports for callers. 

FOR FURTHER INFORMATION CONTACT: 

Rashaun Roberts, Ph.D., Designated 

Federal Officer, NIOSH, CDC, 1090 

Tusculum Avenue, Mailstop C–24, 

Cincinnati, Ohio 45226, Telephone: 

(513) 533–6800, Email: ocas@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Background: The Advisory Board was 

established under the Energy Employees 

Occupational Illness Compensation 

Program Act of 2000 to advise the 

President on a variety of policy and 

technical functions required to 

implement and effectively manage the 

new compensation program. Key 

functions of the Advisory Board include 

providing advice on the development of 

probability of causation guidelines that 

have been promulgated by the 

Department of Health and Human 

Services (HHS) as a final rule; advice on 

methods of dose reconstruction, which 

have also been promulgated by HHS as 

a final rule; advice on the scientific 

validity and quality of dose estimation 

and reconstruction efforts being 

performed for purposes of the 

compensation program; and advice on 

petitions to add classes of workers to the 

Special Exposure Cohort (SEC). In 

December 2000, the President delegated 

responsibility for funding, staffing, and 

operating the Advisory Board to HHS, 

which subsequently delegated this 

authority to CDC. NIOSH implements 

this responsibility for CDC. 

The charter was issued on August 3, 

2001, renewed at appropriate intervals, 

and rechartered under Executive Order 

13889 on March 22, 2020, and will 

terminate on March 22, 2022. 

Purpose: The Advisory Board is 

charged with (a) providing advice to the 

Secretary, HHS, on the development of 

guidelines under Executive Order 

13179; (b) providing advice to the 

Secretary, HHS, on the scientific 

validity and quality of dose 

reconstruction efforts performed for this 

program; and (c) upon request by the 

Secretary, HHS, advise the Secretary on 

whether there is a class of employees at 

any Department of Energy facility who 

were exposed to radiation but for whom 

it is not feasible to estimate their 

radiation dose, and on whether there is 

reasonable likelihood that such 

radiation doses may have endangered 

the health of members of this class. 

SDRR was established to aid the 

Advisory Board in carrying out its duty 

to advise the Secretary, HHS, on dose 

reconstruction. 

Matters To Be Considered: The agenda 

will include discussions on the 

following dose reconstruction program 

quality management and assurance 

activities: Dose reconstruction cases 

under review from Set 30, possibly 

including cases involving the Hanford 

site and discussion of changes in SDRR 

selection criteria based on SC&A 

document, ‘‘Summary Dose 

Reconstruction Information,’’ dated 

December 20, 2021. Agenda items are 

subject to change as priorities dictate. 

For additional information, please 

contact Toll Free 1 (800) CDC–INFO. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–05428 Filed 3–14–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Board of Scientific Counselors, 

National Center for Injury Prevention 

and Control, (BSC, NCIPC) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

CDC announces the following meeting 

for the Board of Scientific Counselors, 

National Center for Injury Prevention 

and Control, (BSC, NCIPC). This is a 

virtual meeting and is open to the 

public, limited by the capacity of the 

conference webinar which is 2,000 

participants. Pre-registration is required. 

Time will be available for public 

comment. 

DATES: The meeting will be held on 

April 11, 2022, from 10:00 a.m. to 4:30 

p.m., EDT. The public may submit 

written comments from March 15, 2022 

through April 18, 2022. 

ADDRESSES: Zoom Virtual Meeting. If 

you would like to attend the virtual 

meeting, please pre-register by accessing 

the link at https://

dceproductions.zoom.us/webinar/ 

register/WN_Mi3IYbnQTOmu

EKZBxScBWQ. Instructions to access 

the Zoom virtual meeting will be 

provided in the link following 

registration. 

Meeting Information: There will be a 

public comment period from 3:45 p.m.– 

4:15 p.m., EDT. The public is 

encouraged to register for the BSC, 

NCIPC April 11, 2022, meeting public 

comment period by accessing the link 

provided: https://

www.surveymonkey.com/r/l3hdzb6. 

Individuals wishing to pre-register for 

public comment must do so by 

Wednesday, April 6, 2022, at 5:00 p.m., 

EDT. 

FOR FURTHER INFORMATION CONTACT: 

Arlene Greenspan, DrPH, MPH, PT, 

Associate Director for Science, National 

Center for Injury Prevention and 

Control, Centers for Disease Control and 

Prevention, 4770 Buford Highway NE, 

Mailstop S106–9, Atlanta, Georgia 

30341, Telephone: (770) 488–1279; 

Email address: ncipcbsc@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Board will: (1) Conduct, 

encourage, cooperate with, and assist 

other appropriate public health 

authorities, scientific institutions, and 

scientists in the conduct of research, 

investigations, experiments, 

demonstrations, and studies relating to 

the causes, diagnosis, treatment, control, 

and prevention of injury and violence, 

and other impairments; (2) assist States 

and their political subdivisions in 

preventing intentional and 

unintentional injuries and to promote 

health and well-being; and (3) conduct 

and assist in research and control 

activities related to injury. The Board of 

Scientific Counselors makes 

recommendations regarding policies, 

strategies, objectives, and priorities; and 

reviews progress toward injury 

prevention goals and provides evidence 

in injury prevention-related research 

and programs. In addition, the Board 

provides advice on the appropriate 

balance of intramural and extramural 

research, the structure, progress, and 

performance of intramural programs. 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 50 / Tuesday, March 15, 2022 / Notices 14535 

The Board is designed to provide 

guidance on extramural scientific 

program matters, including the: (1) 

Review of extramural research concepts 

for funding opportunity 

announcements; (2) conduct of 

Secondary Peer Review of extramural 

research grants, cooperative agreements, 

and contracts applications received in 

response to the funding opportunity 

announcements as it relates to the 

Center’s programmatic balance and 

mission; (3) submission of secondary 

review recommendations to the Center 

Director of applications to be considered 

for funding support; (4) review of 

research portfolios, and (5) review of 

program proposals. 

Matters To Be Considered: The agenda 

will include an update on the Traumatic 

Brain Injury (TBI) Research Priorities; 

Older Adult Falls Research Priorities; 

the Diversity, Equity, Belonging, 

Inclusion and Accessibility (DEBIA) 

Strategic Plan; and Health Equity. 

Agenda items are subject to change as 

priorities dictate. 

Public Participation 

Written Public Comment: Written 

comments must be received on or before 

5:00 p.m., EDT, April 18, 2022, by email 

at ncipcbsc@cdc.gov. All written 

comments will be included as part of 

the meeting minutes. 

Oral Public Comment: This meeting 

will include time for members of the 

public to make an oral comment. 

Individuals wishing to pre-register for 

public comment must do so by 

Wednesday, April 6, 2022, at 5:00 p.m., 

EDT. Those pre-registering for public 

comment must also register for the 

meeting using the link below. 

Oral Public Comment Procedure: 

Individuals registered to provide public 

comment will be called upon first to 

speak based on the order of registration, 

followed by others from the public. All 

public comments will be limited to two 

(2) minutes per speaker. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–05429 Filed 3–14–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

SIP22–007, COVID–19 and Women: An 

Assessment of Challenges and Lessons 

Learned to Enhance Public Health 

Emergency Preparedness for Women 

and Families. 

Date: May 11, 2022 

Time: 11:00 a.m.–6:00 p.m., EDT. 

Place: Teleconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Jaya 

Raman, Ph.D., Scientific Review Officer, 

National Center for Chronic Disease 

Prevention and Health Promotion, CDC, 

4770 Buford Highway, Mailstop S107– 

B, Atlanta, Georgia 30341, Telephone: 

(770) 488–6511, Email: JRaman@

cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–05431 Filed 3–14–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Clinical Laboratory Improvement 

Advisory Committee (CLIAC) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

CDC announces the following meeting 

for the Clinical Laboratory Improvement 

Advisory Committee (CLIAC). This 

meeting is open to the public, limited 

only by the webcast lines available. 

Check the CLIAC website on the day of 

the meeting for the web conference link 

https://www.cdc.gov/cliac. Time will be 

available for public comment. 

DATES: The meeting will be held on 

April 13, 2022, from 11:00 a.m. to 6:00 

p.m., EDT, and April 14, 2022, from 

11:00 a.m. to 6:00 p.m., EDT. 

ADDRESSES: This is a virtual meeting. 

Meeting times are tentative and subject 

to change. The confirmed meeting 

times, agenda items, and meeting 

materials including instructions for 

accessing the live meeting broadcast 

will be available on the CLIAC website 

at https://www.cdc.gov/cliac. 

FOR FURTHER INFORMATION CONTACT: 

Nancy Anderson, MMSc, MT(ASCP), 

Senior Advisor for Clinical Laboratories, 

Division of Laboratory Systems, Center 

for Surveillance, Epidemiology and 

Laboratory Services, Office of Public 

Health Scientific Services, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop V24–3, 

Atlanta, Georgia 30329–4018, 

Telephone: (404) 498–2741; 

NAnderson@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: This Committee is charged 

with providing scientific and technical 

advice and guidance to the Secretary, 

HHS; the Assistant Secretary for Health; 

the Director, CDC; the Commissioner, 

Food and Drug Administration (FDA); 

and the Administrator, Centers for 

Medicare and Medicaid Services (CMS). 

The advice and guidance pertain to 

general issues related to improvement in 

clinical laboratory quality and 

laboratory medicine practice and 

specific questions related to possible 

revision of the Clinical Laboratory 

Improvement Amendments of 1988 

(CLIA) standards. Examples include 

providing guidance on studies designed 

to improve safety, effectiveness, 

efficiency, timeliness, equity, and 


khammond on DSKJM1Z7X2PROD with NOTICES